Similarly, integration of an anti-CD19 CAR into the CCR5 site generated T cells that are resistant to HIV infection while maintaining robust antitumor activity against HIV-associated B-cell malignancies in vitro and in vivo [169]. Here, CCR5 is linked to HIV infectious disease.